Stockwatch: Has Sentiment Left the Biopharma Sector?
Executive Summary
Nothing deters investors more than missed quarterly financial expectations, pipeline attrition and formulary restrictions. Allergan, Pfizer and Shire contributed all three to the sector's investment proposition last week.